Semaglutide pill dosage for weight loss: understanding the four-step schedule

Why there are four steps rather than just starting at the full dose

If you've looked up the oral semaglutide schedule and found four numbers where you expected one, that's probably a little deflating. You were hoping to start treatment, not embark on a four-month climb. That frustration makes sense, and it's worth understanding what the steps are actually for.

Semaglutide slows gastric emptying and acts on appetite centres in the brain. Both effects kick in from the very first dose, and for many people, the gastrointestinal consequences (nausea, loose stools, a vague queasiness that tends to hit mid-morning) are sharpest early on. The four-step approach doesn't delay the medicine's effect; it reduces the chance that those early side effects become bad enough to make someone stop. Starting at 1.5 mg for a month, then stepping to 4 mg, then 9 mg, then reaching 25 mg, gives the gut time to adapt at each stage. The Wegovy tablet overview explains the full picture of how the medicine works if you want the wider context.

In the OASIS 4 phase 3 trial, which supported the MHRA's June 2026 approval of these tablets, most gastrointestinal events were mild to moderate and settled over time. The trial reported around 13.6% average weight loss over 64 weeks, and roughly 17% among participants who stayed fully adherent throughout. That second figure is frequently quoted; the first is the more accurate one to hold in mind for most people.

The Rybelsus confusion: why those other tablet strengths aren't part of this ladder

Search for oral semaglutide doses and you'll quickly encounter 3 mg, 7 mg and 14 mg tablet strengths. Those are Rybelsus, the same molecule, a different product, licensed by the MHRA specifically for type 2 diabetes management. They are not rungs on the Wegovy weight-loss ladder. A page covering the 3 mg tablet specifically sets out that distinction in detail, but the short version is this: using Rybelsus for weight loss in the absence of diabetes isn't what it's licensed for, and the dose ranges don't map onto each other cleanly. If weight management is the goal, Wegovy's schedule (1.5, 4, 9, 25 mg) is the licensed one.

This matters practically because some online sellers conflate the two, occasionally listing Rybelsus strengths as though they slot into the weight-loss programme. The full oral semaglutide dosage guide covers this in more depth, including what to do if you've previously been prescribed Rybelsus and are now looking at weight management treatment.

People already stable on the 2.4 mg weekly Wegovy injection may, subject to clinical assessment, move directly to the 25 mg maintenance tablet rather than restarting from 1.5 mg. That's a prescriber's call, made on a case-by-case basis.

How you take each dose shapes how well it works

Oral semaglutide needs a specific absorption window that most other medicines don't require. The tablet must be taken first thing in the morning, before any food or drink other than a small amount of plain water (up to around 120 ml). After swallowing, you wait at least 30 minutes before eating, drinking anything else (including coffee) or taking other oral medicines. Swallow it whole.

The reason is the absorption enhancer (SNAC) co-formulated in the tablet. In an acidic, empty stomach, SNAC briefly raises the local pH around the tablet and opens a small absorption window in the gastric lining. Food, coffee or other medicines in the stomach at the same time close that window. Miss it and you can lose much of the dose's effect for that day. It's a different discipline from an injection, where timing relative to meals doesn't affect absorption.

No refrigeration is needed, room-temperature storage makes these tablets considerably simpler to manage than the weekly pen, especially for travel. For a side-by-side look at how the tablet and injection differ day to day, the oral dose comparison page is a useful reference. If you want to see the full titration laid out visually, there's also a dosage chart for oral semaglutide that maps the schedule week by week.

Who the licensed dosage applies to, and what a prescriber is weighing up

The 1.5–25 mg Wegovy schedule is licensed for adults with a BMI of 30 or above, or 27–29.9 with at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. BMI alone, though, isn't the whole picture, a prescriber is also looking at your medical history, any medicines you already take, and whether these tablets are appropriate given your circumstances.

The tablets aren't recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. They're not licensed for under-18s. Certain conditions (including a history of pancreatitis or medullary thyroid carcinoma) require careful discussion before any GLP-1 medicine is considered. The Wegovy tablet dosing page includes more detail on what affects whether a particular dose step is appropriate for an individual.

Wegovy tablets are not available on the NHS at launch, a NICE appraisal would be needed first, and that process takes time. Private prescription is the current route, which is worth factoring into your thinking. You can find out more about the cost side of things on the Wegovy pill cost page, and our broader weight-loss treatment overview covers how oral semaglutide sits alongside other licensed options. The NHS's own medicines information on semaglutide is a reliable starting point for understanding semaglutide's side effects and safety profile. For the full regulatory record, the MHRA's Wegovy approval announcements set out what the evidence underpins.

If the dosage schedule makes sense and you'd like to find out whether you're clinically suitable, a prescriber at our clinical team can review your consultation the same day. Check your eligibility with a free consultation, no obligation, and a real clinician reads your answers.